W. Harms et al., HDR-brachytherapy boost for residual tumour after external beam radiotherapy in patients with tracheal malignancies, RADIOTH ONC, 52(3), 1999, pp. 251-255
Citations number
17
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Seven inoperable patients with tracheal neoplasms received a high dose rate
(HDR) brachytherapy boost (median 15 Gy, single dose 3-5 Gy) for residual
tumour after external beam radiotherapy (median 50 Gy, 5 x 2 Gy/week). The
median actuarial survival was 34.3 months. The 1-, 2- and 3-year actuarial
survival rates were 85.7%, 85.7% and 32%. Local control was obtained in 5/7
patients. Late toxicity occurred in three patients (stenosis n = 2, hemorr
hage n = 1). Our data indicate, that a HDR brachytherapy boost is effective
and feasible. (C) 1999 Published by Elsevier Science Ireland Ltd. All righ
ts reserved.